摘要
世界卫生组织/国际泌尿病理学2004年分类[WHO(2004)/ISUP]对尿路上皮肿瘤分级标准化进行了有益尝试。在乳头状膀胱肿瘤分类中,新加入了“具低度恶性潜能的乳头状尿路上皮肿瘤(PUNLMP)”条目。WHO(2004)/ISUP尿路上皮肿瘤分类系统与被广泛接受的WHO1973年分类相比,具有数项潜在优势:(1)详细定义了不同瘤前病变和不同分级肿瘤的形态标准,包括更加标准化地定义了非浸润性乳头状尿路上皮性肿瘤(NIPUT)的组织学分级标准,有利于提高病理医师间诊断的可重复性;(2)建立了统一的术语和一般性定义;(3)力图将肿瘤分类系统的术语设计得与尿细胞学术语更为吻合,使得细胞-组织学的对应关系更易于操作,为指导改善患者的治疗提供了可能性;(4)去除了模糊的分类级别,如TCC分级Ⅰ~Ⅱ,TCC分级Ⅱ~Ⅲ;(5)单独列出了具有高危险进展为浸润性癌的肿瘤。
出处
《中华病理学杂志》
CAS
CSCD
北大核心
2006年第9期520-522,共3页
Chinese Journal of Pathology
参考文献22
-
1Oyasu R.World Health Organization and International Society of Urological Pathology classification and two-number grading system of bladder tumors.Cancer,2000,88:1509-1512.
-
2Oosterhuis JW,Schapers RF,Janssen-Heijnen ML,et al.Histological grading of papillary urothelial carcinoma of the bladder:prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems.J Clin Pathol,2002,55:900-905.
-
3Mikuz G.The reliability and reproducibility of the different classifications of bladder cancer.In:Hauptmann S,Dietel M,eds.Surgical pathology update 2001.Berlin:ABW-Wissenschaftsverlag,2001.114-115.
-
4Bostwick DG,Mikuz G.Urothelial papillary (exophytic) neoplasms.Virchows Arch,2002,441:109-116.
-
5Cheng L,Bostwick DG.World Health Organization and International Society of Urological Pathology classification and two-number grading system of bladder tumors:reply.Cancer,2000,88:1513-1516.
-
6Bostwick DG,Ramnani D,Cheng L.Diagnosis and grading of bladder cancer and associated lesions.Urol Clin North Am,1999,26:493-507.
-
7Bol M,Baak GP,Buhr-Wildhagen S,et al.Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta,T1 urothelial carcinoma of the bladder.J Urol,2003,169:1291 -1294.
-
8Eble JN,Sauter G,Epstein JI,et al,eds.World Health Organization classification of tumours.Pathology and genetics of tumours of the urinary system and male genital organs.Lyon:IARC Press,2004.90-115.
-
9Gomez-Roman JJ,Saenz P,Molina M,et al.Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.Clin Cancer Res,2005,11:459-465.
-
10Cheng L,Neumann RM,Nehra A,et al.Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma.Cancer,2000,88:1663-1670.
同被引文献24
-
1宋希双,张志伟,车翔宇,姜涛,李先承,殷积斌.凋亡抑制基因Livin在膀胱癌中的表达及意义[J].中华泌尿外科杂志,2006,27(S1):37-39. 被引量:23
-
2韦萍,陆鸣,周小鸽,郑媛媛,黄受方.膀胱低恶性潜能乳头状尿路上皮肿瘤特点及对其本质的认识[J].诊断病理学杂志,2005,12(2):146-148. 被引量:8
-
3Yin H, Leong AS. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up[J]. Am J Clin Pathol,2004, 121 (5) :679 - 687.
-
4Holmang S, Hedelin H, Anderstrom C, et al. Recurrence and progression in low grade papillary urothelial tumors[ J]. J Urol, 1999, 162(3) :702 - 70?.
-
5Eble JN, sauter G, Epstein JI, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs[ M]. Lyon: IARC Press,2004. 90.
-
6Suwa Y, Takano Y, Iki M, et al. Prognostic significance of Ki-67 expression in transitional cell bladder carcinoma after radical cystectomy[J]. Pathol Res Pract, 1997,193(8) :551 - 556.
-
7Pich A, Chiusa L, Formiconi A, et al. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade(grade 1)papillary carcinomas of the bladder[J]. Am J Surg Pathol,2001,25(12) : 1528 - 1533.
-
8Sou Z, Su W, Holm R, et al. Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinoma [J].Anticancer Res, 1995,15 (6B) : 2797 - 2798.
-
9Eble JN, Sauter G, Epstein JI, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs[M]. Lyon:IARC Press,2004:90-115.
-
10王浩飞,徐兆平,黄欣,赵菊平,谢欣,何威,张翀宇,芮文斌,孙福康,祝宇,周文龙,吴瑜璇,沈周俊.膀胱低度恶性潜能乳头状泌尿上皮肿瘤的病理和临床特征[J].肿瘤,2008,28(1):74-76. 被引量:6
引证文献5
-
1时淑舫,陈书媛,周小鸽,黄受方.非浸润性膀胱尿路上皮肿瘤中Ki-67、c-erbB-2的表达及意义[J].诊断病理学杂志,2009,16(1):25-28. 被引量:2
-
2开金云,刘忠平,刘骏.膀胱低度恶性潜能乳头状尿路上皮肿瘤临床病理分析[J].中国现代医生,2010,48(7):75-76. 被引量:1
-
3谢文华,何屹,顾燕琴,吴晓鸣,曹益方,陈昊,陈斌,何顺亮,陆林峰,邬凌峰.Livin、Survivin、P16、34βE12在预测膀胱低度恶性潜能泌尿上皮乳头状肿瘤复发中的临床意义[J].全科医学临床与教育,2017,15(4):368-371.
-
4谢文华,何屹.膀胱低度恶性潜能乳头状尿路上皮肿瘤诊治新进展[J].国际泌尿系统杂志,2017,37(6):933-937. 被引量:1
-
5刘艳艳,谭曦,彭雪.妊娠合并膀胱低度恶性潜能乳头状尿路上皮肿瘤并文献复习[J].中华妇幼临床医学杂志(电子版),2023,19(2):212-218.
二级引证文献4
-
1开金云,刘忠平,刘骏.膀胱低度恶性潜能乳头状尿路上皮肿瘤临床病理分析[J].中国现代医生,2010,48(7):75-76. 被引量:1
-
2魏勇,张庭,李蓓.吉西他滨联合奥沙利铂治疗尿路上皮肿瘤的疗效[J].中国老年学杂志,2013,33(22):5579-5580. 被引量:8
-
3王丽娟,孙晶,侯红梅,彭俊华.甲状腺乳头状癌中C-erbB-2、Ki-67的表达及意义[J].中国医师杂志,2014,16(1):76-78. 被引量:2
-
4郑建瑞,林茂华,李婷,毛瑛玉.膀胱乳头状尿路上皮肿瘤中CD44v6与CK20的表达情况及其临床病理意义[J].医疗装备,2019,32(10):1-2. 被引量:1
-
1王冬梅,麦筱莉,杨献峰,牡丹,周正杨,朱斌.低度恶性潜能乳头状尿路上皮肿瘤二例[J].中华放射学杂志,2010,44(8):887-888. 被引量:2
-
2罗启翅,张薇珊,夏勤.膀胱低度恶性潜能的乳头状尿路上皮肿瘤的临床病理分析[J].中医学报,2013,28(B12):467-467.
-
3程亮,赵明.重新评价非浸润性乳头状尿路上皮肿瘤的组织学分级[J].中华病理学杂志,2014,43(12):848-852. 被引量:6
-
4开金云,刘忠平,刘骏.膀胱低度恶性潜能乳头状尿路上皮肿瘤临床病理分析[J].中国现代医生,2010,48(7):75-76. 被引量:1
-
5韦萍,陆鸣,周小鸽,郑媛媛,黄受方.膀胱低恶性潜能乳头状尿路上皮肿瘤特点及对其本质的认识[J].诊断病理学杂志,2005,12(2):146-148. 被引量:8
-
6鲍镇美.尿路上皮性肿瘤的诊断[J].中华泌尿外科杂志,1999,20(5):317-320. 被引量:6
-
7张华.膀胱低度恶性潜能乳头状尿路上皮肿瘤十例临床病理分析[J].中国医师进修杂志,2011,34(5):74-75. 被引量:2
-
8曹雅静,范嫏娣,冯起庆,关剑,张丽.膀胱低度恶性潜能乳头状尿路上皮肿瘤12例临床病理分析[J].中国肿瘤临床,2006,33(13):771-773. 被引量:2
-
9郑悦,潘丹玲.膀胱低度恶性潜能乳头状尿路上皮肿瘤40例临床病理分析[J].福建医药杂志,2010,32(4):77-78.
-
10孟红,吴宁,周巧,辜艳.膀胱低度恶性潜能乳头状尿路上皮肿瘤33例临床病理分析[J].华西医学,2007,22(2):272-273. 被引量:2